Metformin and Weight Loss in Obese Women with Polycystic Ovary Syndrome: Comparison of Doses

Context: Metformin treatment of women with polycystic ovary syn-drome (PCOS) is widespread, as determined by studies with diverse patient populations. No comparative examination of weight changes or metabolite responses to different doses has been reported. Objective: The aim of this study was to determine whether different doses of metformin (1500 or 2550 mg / d) would have different effects on body weight, circulating hormones, markers of inflammation, and lipid profiles. Design: The study included prospective cohorts randomized to two doses of metformin. Setting: The study was performed at a university teaching hospital with patients from gynecology/endocrinology clinics. Patients: The patients studied were obese (body mass index, 30 to 37 kg/m2; n 42) and morbidly obese (body mass index,37 kg/m2; n 41) women with PCOS